Promising Medical Stocks To Keep An Eye On - August 5th

Key Points

• Five medical stocks to watch include UnitedHealth Group, Hims & Hers Health, Vertex Pharmaceuticals, Pfizer, and STAAR Surgical, which are leading in trading volume within the healthcare sector.
• UnitedHealth Group's stock recently traded at $250.10 with a market capitalization of $226.87 billion, while Hims & Hers Health saw its stock price hit $57.54.
• Vertex Pharmaceuticals focuses on therapies for cystic fibrosis and is valued at $98.48 billion, having recently traded at $383.49.

UnitedHealth Group, Hims & Hers Health, Vertex Pharmaceuticals, Pfizer, and STAAR Surgical are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies operating in the healthcare sector—such as pharmaceutical manufacturers, biotechnology firms, medical-device makers, hospitals, diagnostic laboratories, and health insurers. They give investors exposure to medical research, drug-development pipelines, and healthcare services. Their performance is driven by factors like regulatory approvals, patent lifecycles, clinical-trial outcomes, and demographic trends. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

UnitedHealth Group stock traded up $9.12 during mid-day trading on Tuesday, reaching $250.10. The stock had a trading volume of 17,089,253 shares, compared to its average volume of 12,059,151. The company has a 50-day moving average price of $295.77 and a two-hundred day moving average price of $412.81. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.85 and a quick ratio of 0.85. The company has a market capitalization of $226.87 billion, a price-to-earnings ratio of 10.87, a PEG ratio of 1.50 and a beta of 0.43. UnitedHealth Group has a one year low of $234.60 and a one year high of $630.73.

Read Our Latest Research Report on UNH

Hims & Hers Health (HIMS)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Shares of NYSE:HIMS traded down $5.81 during trading on Tuesday, hitting $57.54. The company's stock had a trading volume of 70,511,010 shares, compared to its average volume of 34,136,801. The company has a 50-day moving average of $53.79 and a 200-day moving average of $44.51. Hims & Hers Health has a 12 month low of $13.47 and a 12 month high of $72.98. The firm has a market cap of $12.88 billion, a price-to-earnings ratio of 84.45, a P/E/G ratio of 2.31 and a beta of 2.08.

Read Our Latest Research Report on HIMS

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

VRTX traded down $88.78 during trading on Tuesday, reaching $383.49. 6,676,976 shares of the company traded hands, compared to its average volume of 1,559,965. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. Vertex Pharmaceuticals has a 12-month low of $377.85 and a 12-month high of $519.88. The firm has a fifty day simple moving average of $456.34 and a 200 day simple moving average of $467.46. The company has a market cap of $98.48 billion, a P/E ratio of -97.98 and a beta of 0.44.

Read Our Latest Research Report on VRTX

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

NYSE PFE traded up $1.16 on Tuesday, hitting $24.69. 70,826,362 shares of the stock were exchanged, compared to its average volume of 45,622,734. Pfizer has a 52-week low of $20.92 and a 52-week high of $30.43. The firm has a market capitalization of $140.34 billion, a P/E ratio of 17.87, a P/E/G ratio of 0.85 and a beta of 0.52. The stock has a fifty day moving average price of $24.37 and a two-hundred day moving average price of $24.53. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Read Our Latest Research Report on PFE

STAAR Surgical (STAA)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

STAA traded up $8.46 on Tuesday, hitting $26.95. The company had a trading volume of 36,292,748 shares, compared to its average volume of 1,177,652. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $41.00. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -18.72 and a beta of 0.61. The stock has a fifty day moving average price of $17.53 and a 200-day moving average price of $18.26.

Read Our Latest Research Report on STAA

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.